Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (1608)	6/3/2002 1:30:16 PM
From: Captain Jack	Respond to of 1870

New 52 week low,,, w/o good news many more on the way,,, brokerages dropping it to 'hold'.. nice way of saying 'flush'.

To: bob zagorin who wrote (1608)	6/3/2002 1:42:21 PM
From: Elmer	Read Replies (2) \| Respond to of 1870

I don't get it. Why would Aventis SA make the investment in GNTA without having a high degree of confidence in the ongoing results of the PIII trials? They are open label. Now, according to the PR, Aventis wants a larger sample which will delay the results of the study. Anybody agree with the Street.com that the expansion of the study suggests lack of efficacy or is it an expansion to get a larger sample to deal with a much more difficult FDA. After the BMY/IMCL fiasco, Aventis must have done extensive due diligence and talked to those running the trials about the results. This is too strange.